Neurocrine axes Takeda-partnered depression program, switches focus for seizure drug after PhII failures
Neurocrine Biosciences has been hit with a pair of mid-stage failures for its partnered candidates in major …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
